Glomus jugulare tumor: Tumor control and complications after stereotactic radiosurgery

Head & Neck ◽  
2002 ◽  
Vol 24 (4) ◽  
pp. 332-339 ◽  
Author(s):  
Robert L. Foote ◽  
Bruce E. Pollock ◽  
Deborah A. Gorman ◽  
Paula J. Schomberg ◽  
Scott L. Stafford ◽  
...  
Keyword(s):  
Stereotactic Radiosurgery ◽  
Tumor Control ◽  
Glomus Jugulare Tumor ◽  
Glomus Jugulare

Stereotactic Radiosurgery for Glomus Jugulare Tumors: Long-Term Tumor Control Using 3D Volumetric Tumor Analysis

2019 ◽  
Author(s):  
Neil Patel ◽  
Matthew Carlson ◽  
Bruce Pollock ◽  
Colin Driscoll ◽  
Brian Neff ◽  
...  
Keyword(s):  
Stereotactic Radiosurgery ◽  
Tumor Control ◽  
Glomus Jugulare

scholarly journals Radiosurgery for glomus jugulare: history and recent progress

2009 ◽  
Vol 27 (6) ◽  
pp. E5 ◽  
Author(s):  
Zachary D. Guss ◽  
Sachin Batra ◽  
Gordon Li ◽  
Steven D. Chang ◽  
Andrew T. Parsa ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Recent Progress ◽  
Primary Treatment ◽  
Tumor Control ◽  
Microsurgical Treatment ◽  
Glomus Jugulare Tumor ◽  
Glomus Jugulare

In this article the authors review the literature for recent studies of radiosurgical treatment for glomus jugulare. These studies demonstrate that radiosurgery results in similar glomus jugulare tumor control and a superior morbidity profile compared with surgical treatment. In addition, patients treated with radiosurgery usually remain stable clinically or improve. Given the indolent nature of these tumors, however, more follow-up is required to ensure that the immediate benefits are lasting. These preliminary reports demonstrate that the use of radiosurgery as a primary treatment for glomus jugulare should be extended to encompass more of the patients who are currently assigned to microsurgical treatment.

Malignant Familial Glomus Jugulare Tumor: A Case Report

Skull Base ◽  
2007 ◽  
Vol 17 (S 1) ◽  
Author(s):  
Alessandro Bertuccio ◽  
Antonio Fioravanti ◽  
Stefano Bartolini ◽  
Filippo Badaloni ◽  
Fabio Calbucci
Keyword(s):  
Case Report ◽  
Glomus Jugulare Tumor ◽  
Glomus Jugulare

A Case of Catecholamine-Secreting Glomus Jugulare Tumor: Treatment Strategy and Perioperative Management

Skull Base ◽  
2008 ◽  
Vol 18 (S 01) ◽  
Author(s):  
Hiroaki Motegi ◽  
Shunsuke Terasaka ◽  
Shigeru Yamaguchi ◽  
Hiroyuki Kobayashi ◽  
Katsuyuki Asaoka ◽  
...  
Keyword(s):  
Treatment Strategy ◽  
Perioperative Management ◽  
Tumor Treatment ◽  
Glomus Jugulare Tumor ◽  
Glomus Jugulare

scholarly journals Stereotactic radiosurgery for treating meningiomas eligible for complete resection

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Maximilian I. Ruge ◽  
Juman Tutunji ◽  
Daniel Rueß ◽  
Eren Celik ◽  
Christian Baues ◽  
...  
Keyword(s):  
Adverse Events ◽  
Stereotactic Radiosurgery ◽  
Medical Condition ◽  
Local Tumor Control ◽  
Complete Resection ◽  
Neurological Deficits ◽  
Tumor Control ◽  
Recurrence Rates ◽  
Treatment Volume

Abstract Background For meningiomas, complete resection is recommended as first-line treatment while stereotactic radiosurgery (SRS) is established for meningiomas of smaller size considered inoperable. If the patient´s medical condition or preference excludes surgery, SRS remains a treatment option. We evaluated the efficacy and safety of SRS in a cohort comprising these cases. Methods In this retrospective single-centre analysis we included patients receiving single fraction SRS either by modified LINAC or robotic guidance by Cyberknife for potentially resectable intracranial meningiomas. Treatment-related adverse events as well as local and regional control rates were determined from follow-up imaging and estimated by the Kaplan–Meier method. Results We analyzed 188 patients with 218 meningiomas. The median radiological, and clinical follow-up periods were 51.4 (6.2–289.6) and 55.8 (6.2–300.9) months. The median tumor volume was 4.2 ml (0.1–22), and the mean marginal radiation dose was 13.0 ± 3.1 Gy, with reference to the 80.0 ± 11.2% isodose level. Local recurrence was observed in one case (0.5%) after 239 months. The estimated 2-, 5-, 10- and 15-year regional recurrence rates were 1.5%, 3.0%, 6.6% and 6.6%, respectively. Early adverse events (≤ 6 months after SRS) occurred in 11.2% (CTCEA grade 1–2) and resolved during follow-up in 7.4% of patients, while late adverse events were documented in 14.4% (grade 1–2; one case grade 3). Adverse effects (early and late) were associated with the presence of symptoms or neurological deficits prior to SRS (p < 0.03) and correlated with the treatment volume (p < 0.02). Conclusion In this analysis SRS appears to be an effective treatment for patients with meningiomas eligible for complete resection and provides reliable long-term local tumor control with low rates of mild morbidity.

Sign in / Sign up

Export Citation Format

Share Document